You just read:

European Commission Adopts European Medicines Agency's Opinion Confirming Pioglitazone-Containing Medicines Remain a Valid Treatment Option for Appropriate Type 2 Diabetes Patients

News provided by

Takeda Pharmaceutical Company Limited

10 Jan, 2012, 07:00 GMT